Expression of p53 and prognosis in children with malignant gliomas

New England Journal of Medicine

Volumn 346, Issue 6, 2002, Pages 420-427

  Pollack, Ian F ^a   Finkelstein, Sydney D ^a   Woods, Jeffrey ^a   Burnham, Judith ^a   Holmes, Emiko J ^a   Hamilton, Ronald L ^a   Yates, Allan J ^a   Boyett, James M ^a   Finlay, Jonathan L ^a   Śposto, Richard ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENES, P53; GLIOMA; HUMANS; INFANT; MUTATION; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037034253     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012224     Document Type: Article

References (58)

1. Brain tumors in children
2. Incidence of malignant tumors in U.S. children
3. Resection, biopsy, and survival in malignant glial neoplasms: A retrospective study of clinical parameters, therapy, and outcome
4. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults
5. Long-term survival in patients with glioblastoma multiforme
6. Long-term survival in patients with malignant astrocytoma
7. Ten-year survival among patients with supratentorial astrocytomas grade III and IV
8. High-grade astrocytomas in children: Radiologically complete resection is associated with an excellent long-term prognosis
9. Histological typing of tumours of the central nervous system
10. A molecular genetic model of astrocytoma histopathology
11. INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines
12. Subsets of glioblastoma multiforme defined by molecular genetic analysis
13. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors
14. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas
15. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
16. 1-S transition control gene abnormalities
17. Clonal genomic alterations in glioma malignancy stages
18. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades
19. Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme
20. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25
21. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas
22. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
23. Progression as exemplified by human astrocytic tumors
24. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood
25. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood
26. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations
27. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas
28. ARF gene deletion in high-grade adult and pediatric astrocytomas
29. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas
30. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen
31. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial: A report from the Children's Cancer Study Group
32. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression
33. p53 mutations in human cancers
34. K-ras-2 and p53 genotyping of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses
35. Whole genome amplification and molecular genetic analysis of DNA from paraffin-embedded prostate adenocarcinoma tumor tissue
36. Genotypic classification of colorectal adenocarcinoma: Biologic behavior correlates with K-ras-2 mutation type
37. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
38. An immunochemical analysis of the human nuclear phosphoprotein p53: New monoclonal antibodies and epitope mapping using recombinant p53
39. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
40. When is a high-grade astrocytoma (HGA) not a HGA? Results of a central review of 226 cases of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and other-HGA (Oth-HGA) by five neuropathologists
41. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
42. Defying death after DNA damage
43. Cancer therapy meets p53
44. p53 status and the efficacy of cancer therapy in vivo
45. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer
46. Accumulation of nuclear p53 and tumor progression in bladder cancer
47. Clinical implications of the p53 tumor-suppressor gene
48. p53 point mutation and survival in colorectal cancer patients
49. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy
50. The lack of a role of p53 in astrocytomas in pediatric patients
51. Alterations of the TP53 gene in human gliomas
52. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade, and anaplastic astrocytomas
53. The complexity of p53 modulation: Emerging patterns from divergent signals
54. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value
55. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma
56. Age and TP53 mutation frequency in childhood malignant gliomas: Results in a multi-institutional cohort